Benutzer: Gast  Login
Titel:

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.

Dokumenttyp:
Article; Journal Article
Autor(en):
Rugo, Hope S; Ettl, Johannes; Hurvitz, Sara A; Gonçalves, Anthony; Lee, Kyung-Hun; Fehrenbacher, Louis; Mina, Lida A; Diab, Sami; Woodward, Natasha E; Yerushalmi, Rinat; Goodwin, Annabel; Blum, Joanne L; Martin, Miguel; Quek, Ruben G W; Tudor, Iulia Cristina; Bhattacharyya, Helen; Gauthier, Eric; Litton, Jennifer K; Eiermann, Wolfgang
Abstract:
Background: Talazoparib is a poly(adenosine diphosphate-ribose) polymerase inhibitor that causes death in cells with breast cancer susceptibility gene 1 or 2 (BRCA1/2) mutations. Methods: EMBRACA (NCT01945775) was a randomized phase III study comparing efficacy, safety, and patient-reported outcomes (PROs) of talazoparib (1 mg) with physician's choice of chemotherapy (PCT: capecitabine, eribulin, gemcitabine, vinorelbine) in locally advanced or metastatic breast cancer with a germline BRCA1/2 (g...     »
Zeitschriftentitel:
JNCI Cancer Spectr
Jahr:
2020
Band / Volume:
4
Heft / Issue:
1
Volltext / DOI:
doi:10.1093/jncics/pkz085
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/32337496
TUM Einrichtung:
Frauenklinik und Poliklinik
 BibTeX